Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

Open access

Abstract

Multiple myeloma is a genetically complex and heterogenous malignancy with a 5-year survival rate of approximately 60%. Despite advances in therapy, patients experience cycles of remission and relapse, with each successive line of therapy associated with poorer outcomes; therefore, therapies with different mechanisms of action against new myeloma antigens are needed. G protein-coupled receptor class C group 5 member D (GPRC5D) has emerged as a novel therapeutic target for the treatment of multiple myeloma. We review the biology and target validation of GPRC5D, and clinical data from early phase trials of GPRC5D-targeting bispecific antibodies, talquetamab and forimtamig, and chimeric antigen receptor T cell (CAR-T) therapies, MCARH109, OriCAR-017, and BMS-986393. In addition to adverse events (AEs) associated with T-cell-redirection therapies irrespective of target, a consistent pattern of dermatologic and oral AEs has been reported across several trials of GPRC5D-targeting bispecific antibodies, as well as rare cerebellar events with CAR-T therapy. Additional studies are needed to understand the underlying mechanisms involved in the development of skin- and oral-related toxicities. We review the strategies that have been used to manage these GPRC5D-related toxicities. Preliminary efficacy data showed overall response rates for GPRC5D-targeting T-cell-redirecting therapies were ≥64%; most responders achieved a very good partial response or better. Pharmacokinetics/pharmacodynamics showed that these therapies led to cytokine release and T-cell activation. In conclusion, results from early phase trials of GPRC5D-targeting T-cell-redirecting agents have shown promising efficacy and manageable safety profiles, including lower infection rates compared with B-cell maturation antigen- and Fc receptor-like protein 5-targeting bispecific antibodies. Further clinical trials, including those investigating GPRC5D-targeting T-cell-redirecting agents in combination with other anti-myeloma therapies and with different treatment modalities, may help to elucidate the future optimal treatment regimen and sequence for patients with multiple myeloma and improve survival outcomes. Video Summary.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41408-023-00966-9

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Structure of G protein–coupled receptor class C group 5 member D (GPRC5D). Graphical representation of GPRC5D showing the transmembrane region, which crosses the lipid bilayer seven times, and short extracellular N-terminal domain.
Fig. 1 Structure of G protein–coupled receptor class C group 5 member D (GPRC5D). Graphical representation of GPRC5D showing the transmembrane region, which crosses the lipid bilayer seven times, and short extracellular N-terminal domain.CC BY · PubMed Central
Fig. 2 Expressionof G protein–coupled receptor class C group 5 member D (GPRC5D) in healthy tissues and in multiplemyeloma (MM) versus other cancer types. The first panel (A) shows mRNA expression levels of GPRC5D across a range of healthy tissues. The second panel (B) shows mRNA expression levels of GPRC5D in multiple myeloma compared with expression levels observed across a range of hematological and solid tumor malignancies. ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, CML chronic myelogenous leukemia, DLBCL diffuse large B- cellly mphoma, NSC non-small cell. Reproduced from Smith EL, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):eaau7746.
Fig. 2 Expressionof G protein–coupled receptor class C group 5 member D (GPRC5D) in healthy tissues and in multiplemyeloma (MM) versus other cancer types. The first panel (A) shows mRNA expression levels of GPRC5D across a range of healthy tissues. The second panel (B) shows mRNA expression levels of GPRC5D in multiple myeloma compared with expression levels observed across a range of hematological and solid tumor malignancies. ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, CML chronic myelogenous leukemia, DLBCL diffuse large B- cellly mphoma, NSC non-small cell. Reproduced from Smith EL, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):eaau7746.CC BY · PubMed Central
Fig. 3 Structure of bispecific antibodies and GPRC5D-targeting CAR-T therapies. The first panel (A) shows a generalized structure ofGPRC5D-targeting bispecific antibodies with the Fc region and CD3 and antigen-binding regions depicted. The second panel (B) shows the structure of CAR-T therapies with the target scFv and spacer regions and costimulatory and CD3 signaling domains depicted.
Fig. 3 Structure of bispecific antibodies and GPRC5D-targeting CAR-T therapies. The first panel (A) shows a generalized structure ofGPRC5D-targeting bispecific antibodies with the Fc region and CD3 and antigen-binding regions depicted. The second panel (B) shows the structure of CAR-T therapies with the target scFv and spacer regions and costimulatory and CD3 signaling domains depicted.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

See all 120

Metadata

Authors
Rodriguez-Otero, P., van de Donk, N. W. C. J., Pillarisetti, K., Cornax, I., Vishwamitra, D., Gray, K., Hilder, B., Tolbert, J., Renaud, T., Masterson, T., Heuck, C., Kane, C., Verona, R., Moreau, P., Bahlis, N., & Chari, A.
Affiliations
  • Janssen Scientific Affairs (United States) (US)
  • Janssen Research & Development (United States) (US)
  • Centre Hospitalier Universitaire de Nantes (FR)
  • University of Calgary (CA)
  • Icahn School of Medicine at Mount Sinai (US)
Venue
Blood Cancer Journal
Published
2024-02-02
Volume
14
Issue
1
Pages
24-24
ISSN
2044-5385 (ISSN-L)
OpenAlex
W4391482982
Cited by
113
References
62
Citations by year
2026: 32 · 2025: 51 · 2024: 30
FWCI
8.96
Type
journal article
Language
en
Open access
Licence
Locations
  • Blood Cancer Journal (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
Funders
Janssen Research and Development
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
GPRC5D, multiple myeloma, talquetamab, bispecific antibodies, CAR T-cell therapy, T cell redirection, skin toxicity, oral toxicity, cerebellar toxicity, cytokine production, pharmacokinetics, pharmacodynamics, treatment efficacy
MeSH terms
Receptors, Chimeric Antigen, Humans, Multiple Myeloma, Neoplasm Recurrence, Local, Immunotherapy, Adoptive, Antibodies, Bispecific, Receptors, G-Protein-Coupled

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. https://app.cochat.ai/papers/10.1038/s41408-023-00966-9
The paper
Rodriguez-Otero, P., van de Donk, N. W. C. J., Pillarisetti, K., Cornax, I., Vishwamitra, D., Gray, K., Hilder, B., Tolbert, J., Renaud, T., Masterson, T., Heuck, C., Kane, C., Verona, R., Moreau, P., Bahlis, N., & Chari, A. (2024). GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer Journal. https://doi.org/10.1038/s41408-023-00966-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.